M&A / Deals

MSD concludes Terns acquisition to expand CML pipeline

Pharmaceutical Business Review

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD.

Hematology

Read full story

pharminent May 6, 2026 (Last updated: May 6, 2026)

Pharmaceutical Business Review

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD.

Hematology

Read full story

Related Stories

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise